This Letter of Intent involves
Title: True Nature Signs Letter of Intent to Acquire Third Atlanta Compounder
Industry: Software and Programming Sector: Technology
True Nature Signs Letter of Intent to Acquire Third Atlanta Compounder
Innovation Compounding’s Founder Is Slated For Board Role, COO Slot
MAY 23, 2016 - Atlanta, Georgia - True Nature Holding, Inc. (OTCQB:TNTY, “the Company”) today announced that it has entered into a letter of intent for the acquisition of Innovation Compounding, based in Kennesaw, Georgia, a suburb of Atlanta. Dr. Shawn Hodges, founder of Innovation, has been offered the position of Chief Operating Officer and a position on the Board of Directors of the Company, subject to approval.
Innovation Compounding is a compounding pharmacy that supports over 1,400 prescribers, 17,000 patients and 43,000 prescriptions annually. Their product specialties include men’s and women’s health, pain management, weight loss management, allergy treatments and nutritional therapy. Their corporate web site is: http://innovationcompounding.com
Dr. Hodges graduated with a Doctorate in Pharmacy from Texas Tech University School of Pharmacy in 2001. Upon graduation, he was awarded a one-year fellowship program with Eli Lilly where he researched the drug approval process by serving as a regulatory liaison between FDA and Lilly. “We see Dr. Hodges playing a key role in our growth plans in both operations, and product development. His insight and market knowledge has led to a large and growing product set, which we believe will create increased revenues as we move toward a national marketing presence from the current regional emphasis,” said Steve Keaveney, CEO of True Nature.
“The consolidation of the compounding marketplace will create profitable opportunities for those well capitalized companies who can acquire the product sales that had previously gone to the smaller operators. With an emphasis on quality, well qualified staff and custom